Key result
High baseline sclerostin linked to ~75% higher MACE risk over 9 years.
Why the study?
The role of baseline sclerostin levels in long-term cardiovascular outcomes in patients undergoing coronary angiography without significant renal impairment was unclear.
Do high baseline sclerostin levels predict a higher rate of major cardiovascular events in patients undergoing coronary angiography?
Cohort (n=205)
No
Do high baseline sclerostin levels predict a higher rate of major cardiovascular events in patients undergoing coronary angiography?
Elevated baseline sclerostin levels are associated with an increased long-term risk of major cardiovascular events and death in patients undergoing coronary angiography.
Answers are grounded in this paper and cite their sources.
May support risk stratification post-angiography; hypothesis-generating and requires prospective validation before clinical use.
Sclerostin might play a role in atherosclerosis development. This study aimed to analyze the impact of baseline sclerostin levels on 9-year outcomes in patients without significant renal function impairment and undergoing coronary angiography. The primary study endpoint was the rate of major cardiovascular events (MACE), defined as a combined rate of myocardial infarction (MI), stroke, or death at 9 years. We included 205 patients with a mean age of 62.9 ± 0.6 years and 70.2% male. Median serum sclerostin concentration was 133.22 pg/mL (IQR 64.0–276.17). At 9 years, in the whole population, the rate of MACE was 34.1% (n = 70), MI: 11.2% (n = 23), stroke: 2.4% (n = 5), and death: 20.5% (n = 42). In the high sclerostin (>median) group, we observed statistically significant higher rates of MACE and death: 25.2% vs. 43.1% (HR 1.75, 95% CI 1.1–2.10, p = 0.02) and 14.6% vs. 26.5% (HR 1.86, 95% CI 1.02–3.41, p = 0.049), respectively. Similar relationships were observed in patients with chronic coronary syndrome and SYNTAX 0–22 subgroups. Our results suggest that sclerostin assessment might be useful in risk stratification, and subjects with higher sclerostin levels might have a worse prognosis.
No takes yet. Share an insight, caveat, or question.
Stompór et al. (2021) conducted a cohort in Coronary artery disease (n=205). High baseline sclerostin levels (>median) vs. Low baseline sclerostin levels (≤median) was evaluated on Major cardiovascular events (MACE), defined as a combined rate of myocardial infarction (MI), stroke, or death at 9 years (HR 1.75, 95% CI 1.1-2.10, p=0.02). High baseline sclerostin levels were associated with a significantly higher rate of major cardiovascular events compared to low levels (43.1% vs. 25.2%, HR 1.75) over a 9-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: